Pharmaceutical

CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio

CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.

Aug 2, 2023 - 20:00
CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio
CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.
Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: House Republicans and Democrats duel over drug shortages; F...

Next Article

Atantares raises $13.9m in pre-Series A funding to develop molecular chips

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer

STAT+: ‘Are we better off with the information?’: Exper...

May 7, 2023

Sterilisation Solutions, Equipment and Services for the Pharmaceutical Industry

Sterilisation Solutions, Equipment and Services for the...

Oct 2, 2024

Advancing parenteral packaging production for the future of pharmaceuticals

Advancing parenteral packaging production for the futur...

May 2, 2023